Revolution Medicines Valuation
Is 42Z undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score
1/6Valuation Score 1/6
Below Fair Value
Significantly Below Fair Value
Price-To-Book vs Peers
Price-To-Book vs Industry
Price-To-Book vs Fair Ratio
Analyst Forecast
Share Price vs Fair Value
What is the Fair Price of 42Z when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: Insufficient data to calculate 42Z's fair value for valuation analysis.
Significantly Below Fair Value: Insufficient data to calculate 42Z's fair value for valuation analysis.
Key Valuation Metric
Which metric is best to use when looking at relative valuation for 42Z?
Key metric: As 42Z barely has revenue we use its Price-To-Book Ratio for relative valuation analysis.
| What is 42Z's PB Ratio? | |
|---|---|
| PB Ratio | 6.1x |
| Book | US$1.57b |
| Market Cap | US$9.55b |
| Key Statistics | |
|---|---|
| Enterprise Value/Revenue | 10894.4x |
| Enterprise Value/EBITDA | -13x |
| PEG Ratio | n/a |
Price to Book Ratio vs Peers
How does 42Z's PB Ratio compare to its peers?
| Company | Forward PB | Estimated Growth | Market Cap |
|---|---|---|---|
| Peer Average | 3x | ||
BIO3 Biotest | 2x | 29.3% | €1.4b |
FYB Formycon | 1.4x | 31.5% | €827.2m |
SRT3 Sartorius | 5.5x | 36.4% | €13.4b |
HPHA Heidelberg Pharma | 2.9x | -33.0% | €103.9m |
42Z Revolution Medicines | 6.1x | 7.2% | €9.5b |
Price-To-Book vs Peers: 42Z is expensive based on its Price-To-Book Ratio (6.1x) compared to the peer average (3x).
Price to Book Ratio vs Industry
How does 42Z's PB Ratio compare vs other companies in the DE Biotechs Industry?
Price-To-Book vs Industry: 42Z is expensive based on its Price-To-Book Ratio (6.1x) compared to the European Biotechs industry average (2.4x).
Price to Book Ratio vs Fair Ratio
What is 42Z's PB Ratio compared to its Fair PB Ratio? This is the expected PB Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
| Fair Ratio | |
|---|---|
| Current PB Ratio | 6.1x |
| Fair PB Ratio | n/a |
Price-To-Book vs Fair Ratio: Insufficient data to calculate 42Z's Price-To-Book Fair Ratio for valuation analysis.
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
| Date | Share Price | Average 1Y Price Target | Dispersion | High | Low | 1Y Actual price | Analysts |
|---|---|---|---|---|---|---|---|
| Current | €53.50 | €66.64 +24.6% | 9.5% | €80.24 | €58.78 | n/a | 14 |
| Nov ’25 | €49.00 | €58.10 +18.6% | 13.0% | €75.96 | €50.03 | n/a | 14 |
| Oct ’25 | €40.40 | €53.42 +32.2% | 10.1% | €65.38 | €48.36 | n/a | 14 |
| Sep ’25 | €37.40 | €54.23 +45.0% | 10.4% | €66.86 | €49.46 | n/a | 14 |
| Aug ’25 | €41.80 | €54.66 +30.8% | 10.2% | €67.06 | €49.60 | n/a | 14 |
| Jul ’25 | €36.00 | €42.00 +16.7% | 6.3% | €46.41 | €37.13 | n/a | 12 |
| Jun ’25 | €35.20 | €42.00 +19.3% | 6.3% | €46.41 | €37.13 | n/a | 12 |
| May ’25 | €34.40 | €38.89 +13.1% | 9.0% | €44.85 | €31.77 | n/a | 13 |
| Apr ’25 | €29.20 | €35.51 +21.6% | 8.8% | €40.23 | €31.09 | n/a | 12 |
| Mar ’25 | €27.20 | €34.14 +25.5% | 10.8% | €39.68 | €25.84 | n/a | 11 |
| Feb ’25 | €25.60 | €33.20 +29.7% | 13.8% | €39.56 | €23.92 | n/a | 11 |
| Jan ’25 | €26.40 | €31.70 +20.1% | 16.1% | €39.08 | €23.63 | n/a | 8 |
| Dec ’24 | €21.40 | €31.01 +44.9% | 16.2% | €39.65 | €23.98 | n/a | 8 |
| Nov ’24 | €18.60 | €34.66 +86.4% | 15.5% | €44.37 | €28.32 | €49.00 | 7 |
| Oct ’24 | €26.80 | €34.43 +28.5% | 15.4% | €44.08 | €28.13 | €40.40 | 7 |
| Sep ’24 | €31.20 | €31.37 +0.5% | 8.9% | €36.44 | €27.33 | €37.40 | 7 |
| Aug ’24 | €23.60 | €29.66 +25.7% | 6.7% | €31.87 | €27.32 | €41.80 | 7 |
| Jul ’24 | €24.00 | €28.97 +20.7% | 13.2% | €35.01 | €21.19 | €36.00 | 9 |
| Jun ’24 | €23.20 | €28.97 +24.9% | 13.2% | €35.01 | €21.19 | €35.20 | 9 |
| May ’24 | €20.60 | €29.08 +41.1% | 14.2% | €34.41 | €20.83 | €34.40 | 9 |
| Apr ’24 | €19.50 | €30.53 +56.6% | 15.1% | €35.64 | €21.57 | €29.20 | 9 |
| Mar ’24 | €25.00 | €30.53 +22.1% | 15.1% | €35.64 | €21.57 | €27.20 | 9 |
| Feb ’24 | €24.40 | €27.19 +11.4% | 16.0% | €34.82 | €18.33 | €25.60 | 9 |
| Jan ’24 | €22.20 | €27.66 +24.6% | 16.0% | €35.57 | €18.72 | €26.40 | 9 |
| Dec ’23 | €22.40 | €28.91 +29.1% | 16.8% | €37.72 | €19.85 | €21.40 | 8 |
| Nov ’23 | €20.40 | €30.42 +49.1% | 18.5% | €38.53 | €20.28 | €18.60 | 8 |
Analyst Forecast: Target price is more than 20% higher than the current share price and analysts are within a statistically confident range of agreement.
Discover undervalued companies
Aspen Pharmacare Holdings
R75.5b
Manufactures and supplies specialty and branded pharmaceutical products worldwide.
LDZA
R8.95
7D
0.6%
1Y
4.7%
Amneal Pharmaceuticals
US$2.6b
Develops, manufactures, markets, and distributes generics, injectables, biosimilars, and specialty branded pharmaceutical products worldwide.
2DT
US$7.70
7D
-4.3%
1Y
91.5%
Almirall
€1.8b
A biopharmaceutical company, engages in the purchase, manufacture, storage, and sale of skin-health medicines in Europe, the Middle East, the United States, Asia, and Africa.
E2Z
€8.29
7D
-1.8%
1Y
0.2%